Pancreatic Cancer Research

ResearcherRoswell Park Comprehensive Cancer CenterActive in the last 2 years

Kazuaki Takabe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6435-4241; OpenAlex author ID A5057255416. Sources: OpenAlex.

Their work

Papers
20 (first author 2, last author 13)
Trials
0
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 4 papers · 2021: 3 papers · 2022: 1 paper · 2023: 5 papers · 2024: 1 paper · 2025: none · 2026: 3 papers

Papers 20

  1. Epithelial-Mesenchymal Transition Is Associated With Perineural Invasion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jss.2026.09.014↗
  2. CD73 is associated with glycolysis related metabolic programs and CD8+ T cell suppression in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2026.1873813↗
  3. MKI67 Enrichment Characterizes a Proliferative and Genomically Unstable Phenotype in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers18162631↗
  4. Increased Vitamin C Intake Is Associated With Decreased Pancreatic Cancer Risk. Co-author DOI 10.14740/wjon1854↗
  5. Conjugated Bile Acids Accelerate Progression of Pancreatic Cancer Metastasis via S1PR2 Signaling in Cholestasis. Last author DOI 10.1245/s10434-022-12806-4↗
  6. ASO Author Reflections: How Does Cholestasis Worsen Pancreatic Cancer Progression? First author DOI 10.1245/s10434-022-12946-7↗
  7. Correction: ASO Author Reflections: How Does Cholestasis Worsen Pancreatic Cancer Progression? First author DOI 10.1245/s10434-023-13408-4↗
  8. Pancreatic ductal adenocarcinoma with a high expression of alcohol dehydrogenase 1B is associated with less aggressive features and a favorable prognosis. Last author PMID 37693153↗
  9. High Mesothelin expression in pancreatic adenocarcinoma is associated with aggressive tumor features but not prognosis. Last author PMID 37818071↗
  10. High beta integrin expression is differentially associated with worsened pancreatic ductal adenocarcinoma outcomes. Last author PMID 36628277↗
  11. Annexin A1 Expression Is Associated with Epithelial-Mesenchymal Transition (EMT), Cell Proliferation, Prognosis, and Drug Response in Pancreatic Cancer. Last author DOI 10.3390/cells10030653↗
  12. G2M checkpoint pathway alone is associated with drug response and survival among cell proliferation-related pathways in pancreatic cancer. Last author PMID 34249445↗
  13. A prognostic score based on long-term survivor unique transcriptomic signatures predicts patient survival in pancreatic ductal adenocarcinoma. Last author PMID 34659888↗
  14. Transcriptomic Profile of Lymphovascular Invasion, a Known Risk Factor of Pancreatic Ductal Adenocarcinoma Metastasis. Last author DOI 10.3390/cancers12082033↗
  15. High G2M Pathway Score Pancreatic Cancer is Associated with Worse Survival, Particularly after Margin-Positive (R1 or R2) Resection. Last author DOI 10.3390/cancers12102871↗
  16. A Novel Four-Gene Score to Predict Pathologically Complete (R0) Resection and Survival in Pancreatic Cancer. Last author DOI 10.3390/cancers12123635↗
  17. Fibroblasts as a Biological Marker for Curative Resection in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/ijms21113890↗
  18. High expression of Annexin A2 is associated with DNA repair, metabolic alteration, and worse survival in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.surg.2019.04.011↗
  19. Different Roles of Sphingosine Kinase 1 and 2 in Pancreatic Cancer Progression. Co-author DOI 10.1016/j.jss.2018.06.019↗
  20. Host sphingosine kinase 1 worsens pancreatic cancer peritoneal carcinomatosis. Last author DOI 10.1016/j.jss.2016.05.034↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eriko Katsuta · 6 shared papers, 2016–2026 · strength 1.02
  2. Masanori Oshi · 6 shared papers, 2020–2023 · strength 1.01
  3. Itaru Endo · 6 shared papers, 2020–2023 · strength 1.01
  4. Joy Sarkar · 3 shared papers, 2023 · strength 0.98
  5. Li Yan · 6 shared papers, 2020–2021 · strength 0.85
  6. Caleb Seavey · 2 shared papers, 2026 · strength 0.71
  7. Mashaal Dhir · 2 shared papers, 2026 · strength 0.71
  8. Asama Khan · 2 shared papers, 2026 · strength 0.71
  9. Omar Maen Rashid · 2 shared papers, 2020–2024 · strength 0.45
  10. Matthew H. G. Katz · 3 shared papers, 2020 · strength 0.37
  11. Elizabeth Josephine Olecki · 1 shared paper, 2026 · strength 0.36
  12. Daisuke Ban · 1 shared paper, 2026 · strength 0.32
  13. Hiroaki Aoki · 2 shared papers, 2016–2023 · strength 0.27
  14. Brendan L. Hagerty · 1 shared paper, 2023 · strength 0.26
  15. Hideo Takahashi · 2 shared papers, 2019–2020 · strength 0.26
  16. Maria Pereira · 1 shared paper, 2024 · strength 0.26
  17. Matthew G.K. Benesch · 1 shared paper, 2022 · strength 0.22
  18. Kohei Chida · 1 shared paper, 2023 · strength 0.22
  19. Yuki Hirose · 1 shared paper, 2018 · strength 0.08
  20. Toshifumi Wakai · 1 shared paper, 2018 · strength 0.08
  21. Kizuki Yuza · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.